• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
  

PubMed=1622627; DOI=10.3109/02841869209088892
Lykkesfeldt A.E., Sorensen E.K.
Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1.
Acta Oncol. 31:131-138(1992)

PubMed=7664983; DOI=10.1016/0303-7207(95)03503-Y
Madsen M.W., Reiter B.E., Lykkesfeldt A.E.
Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line.
Mol. Cell. Endocrinol. 109:197-207(1995)

PubMed=16172194; DOI=10.1677/erc.1.00946
Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L., Lykkesfeldt A.E.
Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
Endocr. Relat. Cancer 12:599-614(2005)

PubMed=18824559; DOI=10.1677/ERC-07-0240
Pancholi S., Lykkesfeldt A.E., Hilmi C., Banerjee S., Leary A., Drury S., Johnston S.R.D., Dowsett M., Martin L.-A.
ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
Endocr. Relat. Cancer 15:985-1002(2008)

PubMed=25362855; DOI=10.1038/onc.2014.351
Thrane S., Pedersen A.M., Thomsen M.B.H., Kirkegaard T., Rasmussen B.B., Duun-Henriksen A.K., Laenkholm A.-V., Bak M., Lykkesfeldt A.E., Yde C.W.
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Oncogene 34:4199-4210(2015)